Recent SEC filings highlight significant insider confidence: Patrick J. Heron invested $12 million in Mbx Biosciences (MBX) by acquiring 666,666 shares at $18.00, marking his first purchase in a year, with MBX subsequently trading up 3.2%. Concurrently, United States Antimony (UAMY) CEO Gary C. Evans bought 100,000 shares for $613,200 at $6.13, preceding an 11.4% surge in UAMY's stock price, with his position already showing a 21% gain.
Recent SEC filings reveal significant insider buying activity at Mbx Biosciences (MBX) and United States Antimony (UAMY), signaling strong internal confidence. At Mbx, Patrick J. Heron executed a substantial $12 million investment, acquiring 666,666 shares at $18.00 each. This transaction is particularly noteworthy as it represents his first filed purchase in the past year, coinciding with a 3.2% rise in MBX's stock price on Wednesday. Concurrently, United States Antimony CEO Gary C. Evans invested $613,200 to purchase 100,000 shares at $6.13 per share. The market reacted strongly to this executive endorsement, with UAMY's stock surging 11.4% on the day. The immediate financial validation of this move is underscored by the fact that the CEO's position was up approximately 21.0% at the trading session's high of $7.42.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
